Intensity Therapeutics, Inc. Common stock (INTS)vsVertex Pharmaceuticals Inc (VRTX)
INTS
Intensity Therapeutics, Inc. Common stock
$3.10
-5.49%
HEALTHCARE · Cap: $11.43M
VRTX
Vertex Pharmaceuticals Inc
$542.62
-0.81%
HEALTHCARE · Cap: $141.65B
Smart Verdict
WallStSmart Research — data-driven comparison
VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 62/100 (C+).
INTS
Avoid26
out of 100
Grade: F
VRTX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INTS.
Margin of Safety
+42.4%
Fair Value
$949.93
Current Price
$542.62
$407.31 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INTS
The strongest argument for INTS centers on Price/Book, Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : INTS
The primary concerns for INTS are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
INTS profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
INTS carries more volatility with a beta of 3.04 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (62/100 vs 26/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Intensity Therapeutics, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. By focusing on enhancing the efficacy of immuno-oncology therapies and reducing systemic side effects, the company addresses critical unmet needs in the oncology market. With a robust research and development pipeline, Intensity Therapeutics aims to advance targeted therapies that empower the immune system to fight cancer more effectively, positioning itself as a leader in improving patient outcomes within a complex and rapidly evolving healthcare landscape.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?